TransMedics Q2 revenue up 21% to $189.9M; net income falls to $0.41 EPS; raises FY guidance low end

TransMedics Group, Inc.

Total revenue $189.9M (+21% YoY); product revenue $111.2M (+16%), service revenue $78.8M (+29%).
Net income $14.7M ($0.41 diluted EPS) vs $0.92 prior year; adjusted net income $16.2M ($0.44 adjusted EPS).
Raised low end of FY2026 revenue guidance (excl. PAD Aviation) to $737M-$757M.
Completed strategic investment in PAD Aviation on July 1, 2026 to establish European organ transplant air logistics network.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.